Literature DB >> 2921168

Radiotherapy of the rhabdomyosarcoma R1H of the rat: hyperfractionation--126 fractions applied within 6 weeks.

H P Beck-Bornholdt1, T Maurer, S Becker, M Omniczynski, H Vogler, F Würschmidt.   

Abstract

The effect of a hyperfractionated irradiation treatment on the response of the rhabdomyosarcoma R1H of the rat was studied. Tumors were irradiated under ambient conditions with 126 fractions of X rays, applied in 3 fractions per day with a time interval of 8 +/- 1 hr between fractions on 7 days per week during 6 weeks. The total dose ranged from 54 to 90 Gy, that is the dose per fraction ranged from 0.43 to 0.71 Gy. Tumor response was assessed by tumor control probability and tumor net growth delay. The tumor response to the hyperfractionated treatment was found to be slightly more effective compared to the results obtained in a previous study where treatments with 6, 18, 30, and 42 fractions were applied. Since normal tissues are considerably spared with increased numbers of fractions, clinical studies with hyperfractionation seem to be very promising.

Entities:  

Mesh:

Year:  1989        PMID: 2921168     DOI: 10.1016/0360-3016(89)90488-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  Modelling of carcinogenesis and low-dose hypersensitivity: an application to lung cancer incidence among atomic bomb survivors.

Authors:  Vesna Jacob; Peter Jacob
Journal:  Radiat Environ Biophys       Date:  2003-12-16       Impact factor: 1.925

2.  Adaptive doses of irradiation-an approach to a new therapy concept for bladder cancer?

Authors:  Moshe Schaffer; Silke B Schwarz; Ulrike Kulka; Martin Busch; Eckhart Dühmke
Journal:  Radiat Environ Biophys       Date:  2004-09-29       Impact factor: 1.925

3.  Three-times daily ultrafractionated radiation therapy, a novel and promising regimen for glioblastoma patients.

Authors:  Patrick Beauchesne
Journal:  Cancers (Basel)       Date:  2013-09-25       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.